Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 6:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 17,147 matching trials from the live ClinicalTrials.gov search.
Conditions
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration
Interventions
Selpercatinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
U.S. locations
34
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Duarte, California + 28 more
Conditions
Psoriasis
Interventions
Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
Drug
Lead sponsor
Centocor Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more
Conditions
Cutaneous Lupus Erythematosus (CLE)
Interventions
Lenalidomide
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Glioma, Glioma of Brain, Cancer, Pediatric Cancer, Pediatric Brain Tumor, Astrocytoma, Glioblastoma, Hemispheric
Interventions
Specialized tumor board recommendation
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 21 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
12
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
Conditions
HCV Infection
Interventions
placebo, GS-9190, Peginterferon Alfa 2a, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
48
States / cities
Anaheim, California • Los Angeles, California • Newport Beach, California + 37 more
Conditions
Subarachnoid Hemorrhage, Aneurysmal, Headache
Interventions
Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone, Placebo Pteryogpalatine Fossa Injection
Drug · Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Gainesville, Florida • Miami, Florida • Stuart, Florida + 10 more
Conditions
Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions
IV Dalbavancin, Vancomycin/Linezolid
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
18 Years to 85 Years
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
30
States / cities
Montgomery, Alabama • Anaheim, California • Buena Park, California + 26 more
Conditions
Advanced Solid Tumors
Interventions
MEDI1873
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 7 more
Conditions
Cardiovascular Diseases
Interventions
Incorporation of CT and/or c-MRI derived myocardial scar with 3D electroanatomical mapping (EAM).
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Postoperative Complications, Cataract
Interventions
Bromfenac, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
39
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 34 more
Completed Not applicable Interventional Accepts healthy volunteers

Photograph Quality Rating Scale Study ("PQRS Study")

NCT03246945
Conditions
Dermatology/Skin - Other
Interventions
Instructions on taking photographs provided, see methods
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 17 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Gastric, or Gastroesophageal Junction Adenocarcinoma
Interventions
Tislelizumab, Placebo, Cisplatin, Oxaliplatin, Capecitabine, 5-Fluorouracil
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
6
States / cities
Sacramento, California • Newnan, Georgia • Columbus, Ohio + 3 more
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
Interventions
Palbociclib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Diabetic Foot, Peripheral Arterial Disease
Interventions
PDA-002, Placebo
Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Venous Thrombosis
Interventions
Tapered PICC, Non-tapered PICC
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Epithelial Ovarian Cancer, BRCA2 Mutation, ER+ Breast Cancer, Castrate Resistant Prostate Cancer, BRCA1 Mutation, BRCA Mutation, Endometrial Cancer, Colorectal Cancer, Gastric Cancer
Interventions
ETX-19477
Drug
Lead sponsor
858 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 10 more
Conditions
Magnetic Resonance Imaging
Interventions
Gadoxetate disodium (Eovist/Primovist, BAY86-4873)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 2 Months
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more
Conditions
Bipolar Depression
Interventions
Lumateperone (ITI-007), Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
42
States / cities
Rogers, Arkansas • Cerritos, California • Costa Mesa, California + 39 more
Conditions
Advanced Cancer
Interventions
Ipilimumab, BMS-986218, Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
9
States / cities
Atlanta, Georgia • Boston, Massachusetts • Hackensack, New Jersey + 5 more
Conditions
Cervical Ripening, Induction of Labor
Interventions
MVI 100, MVI 150, MVI 200
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
11
States / cities
Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 8 more
Conditions
Chronic Lymphocytic Leukemia
Interventions
Obinutuzumab, Ublituximab, TGR-1202, Chlorambucil
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
110
States / cities
Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 100 more
Conditions
Breast Carcinoma
Interventions
Mindfulness Relaxation, Functional Magnetic Resonance Imaging, Biospecimen Collection, Questionnaire Administration
Behavioral · Procedure · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Internal Carotid Artery Stenosis, Cognitive Impairment
Interventions
Revascularization, Intensive Medical Management (IMM) alone
Procedure · Other
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 86 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
56
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 45 more
Recruiting No phase listed Observational Accepts healthy volunteers

UPenn Observational Research Repository on Neurodegenerative Disease

NCT04715399
Conditions
Frontotemporal Degeneration(FTD), Primary Progressive Aphasia(PPA), Familial Frontotemporal Lobar Degeneration (fFTLD), Amyotrophic Lateral Sclerosis(ALS), Lewy Body Disease(LBD), Progressive Supranuclear Palsy(PSP), Corticobasal Syndrome(CBS), Posterior Cortical Atrophy(PCA), Alzheimer's Disease(AD)
Interventions
No intervention
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2070
U.S. locations
1
States / cities
Philadelphia, Pennsylvania